Abbott Acquires Exact Sciences for $21B

Abbott Laboratories acquisition of Exact Sciences for $21 billion marks a significant expansion into the cancer testing market. Exact Sciences, known for its innovative early cancer detection tests like Cologuard, will bring its strong brand and expertise under Abbotts umbrella. The deal, valued at $105 per share, is expected to boost Abbotts diagnostics sales and expand its international reach, particularly with Exact Sciences Cancerguard blood test.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.